The Effectiveness of 6-month Treatment with Citalopram in Korean Panic Disorder Patients: A Prospective, Open-labeled, Multi-Center Trial.
- Author:
In Soo LEE
1
;
Jong Chul YANG
;
Young Hee CHOI
;
Jung Bum KIM
;
Sang Yeol LEE
;
Seung Hwan LEE
;
Kang Seob OH
;
Bum Hee YU
Author Information
1. Youngkwang Christian Sin Ha Hospital, Youngkwang, Korea.
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Panic disorder;
Citalopram;
Treatment outcome;
Quality of life
- MeSH:
Anxiety;
Appointments and Schedules;
Axis, Cervical Vertebra;
Citalopram*;
Depression;
Humans;
Panic Disorder*;
Panic*;
Prospective Studies*;
Quality of Life;
Treatment Outcome
- From:Korean Journal of Psychopharmacology
2006;17(2):203-211
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The authors examined the efficacy of citalopram, and its effect on the quality of life in patients with panic disorder. METHOD: Seventy three patients who had panic disorder were recruited for this study. They did not have major depression and other axis I diseases. They were scheduled to be examined 4 times (at baseline, 4, 12 and 24 weeks) and took citalopram for 24 weeks with a flexible dosing schedule. The primary efficacy variables were the response and remission rates (response: HAMA total score decreased by at least 50% from baseline; remission: HAMA total score < or = 7). Other variables included the Hamilton Rating Scale for Depression, Panic Disorder Severity Scale (PDSS), Acute Panic Inventory, Clinical Global Impression Scale and Sheehan Disabilities Scale (SDS). RESULTS: The number of patients who completed 24 weeks of treatment was 33 (45.2%). Forty patients who were dropped out consisted of 4 patients with symptom improvement and 36 patients with failure to return. Response/remission rates were 56.2/31.5% in the last-observation-carried-forward methods and 87.9/69.7% in the observed case data. Treatment with citalopram improved anxiety and depressive symptoms during 24 weeks on all efficacy measures. By a completed patient analysis, citalopram also significantly improved the disability scores on SDS. In this study, any serious adverse effects were not observed. CONCLUSION: Treatment with citalopram was effective and well-tolerated for the patients with panic disorder, and also improved quality of life in the patients.
